ITP
MCID: THR001
MIFTS: 60

Thrombocytopenia Due to Platelet Alloimmunization (ITP)

Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Immune diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards integrated aliases for Thrombocytopenia Due to Platelet Alloimmunization:

Name: Thrombocytopenia Due to Platelet Alloimmunization 12 15 71
Immune Thrombocytopenia 12 74 20 43 36 15 62
Autoimmune Thrombocytopenia 43 58 29 54 6 71
Immune Thrombocytopenic Purpura 43 71
Thrombocytopenia Due to Immune Destruction 12
Idiopathic Thrombocytopenic Purpura 43
Autoimmune Thrombocytopenic Purpura 43
Auto-Immune Thrombocytopenia 12
Werlhof Disease 43
Itp 43

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:1587
KEGG 36 H01240
NCIt 50 C3991
SNOMED-CT 67 2897005
ICD10 via Orphanet 33 D69.3
UMLS via Orphanet 72 C0242584
Orphanet 58 ORPHA71203
UMLS 71 C0242584 C0272286 C0398650

Summaries for Thrombocytopenia Due to Platelet Alloimmunization

MedlinePlus Genetics : 43 Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cells called platelets that are needed for normal blood clotting.Affected individuals can develop red or purple spots on the skin caused by bleeding just under the skin's surface. Small spots of bleeding under the skin are called purpura and larger spots are called ecchymoses. People with immune thrombocytopenia can have significant bleeding episodes, such as nose bleeds (epistaxis) or bleeding in the moist lining (mucosae) of the mouth. In severe cases, individuals may have gastrointestinal bleeding or blood in the urine or stool, or heavy and prolonged menstrual bleeding (menorrhagia). In very rare instances, bleeding inside the skull (intracranial hemorrhage) can occur, which can be life-threatening. A greater reduction in platelet numbers is often associated with more frequent bleeding episodes and an increased risk of severe bleeding.While immune thrombocytopenia can be diagnosed at any age, there are two periods when the condition is most likely to develop: early childhood and late adulthood. In children, the reduction in platelets is often sudden, but platelet levels usually return to normal levels within weeks to months. Immune thrombocytopenia in children is often preceded by a minor infection, such as an upper respiratory infection, but the relationship between the infection and immune thrombocytopenia is not clear. In adults, the development of immune thrombocytopenia is usually gradual and the condition tends to persist throughout life.

MalaCards based summary : Thrombocytopenia Due to Platelet Alloimmunization, also known as immune thrombocytopenia, is related to purpura and thrombocytopenic purpura, autoimmune. An important gene associated with Thrombocytopenia Due to Platelet Alloimmunization is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Phagosome and Osteoclast differentiation. The drugs rituximab and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and spleen, and related phenotypes are thrombocytopenia and thromboembolism

KEGG : 36 Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder, and the most common cause of isolated thrombocytopenia in children. Destruction of autoantibody-sensitized platelets by Fc[gamma]R-bearing phagocytic cells in the reticuloendothelial system plays an important role. ITP is diagnosed clinically, based upon onset of thrombocytopenia in the absence of other hematologic abnormalities, or other causes of low platelets, and with a characteristic blood smear. While around 50% of typical childhood acute ITP is preceded by a viral or bacterial infection and commonly resolves within weeks to months without treatment, fewer adult cases are acute and self-resolving. Typical adult primary ITP is very similar clinically to chronic pediatric ITP. Intravenous immunoglobulin (IVIg) treatment and splenectomy (removal of the platelet-destructing organ) are effective treatment options. It has been reported that the activating FCGR2C-ORF genotype predisposes to ITP by altering the balance of activating and inhibitory Fc[gamma]R on immune cells.

PubMed Health : 62 About immune thrombocytopenia: Immune thrombocytopenia (THROM-bo-si-toe-PE-ne-ah), or ITP, is a bleeding disorder. In ITP, the blood doesn't clot as it should. This is due to a low number of blood cell fragments called platelets (PLATE-lets) or thrombocytes (THROM-bo-sites). Platelets are made in your bone marrow along with other kinds of blood cells. They stick together (clot) to seal small cuts or breaks on blood vessel walls and stop bleeding.

Wikipedia : 74 Immune thrombocytopenic purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune... more...

Related Diseases for Thrombocytopenia Due to Platelet Alloimmunization

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Thrombocytopenia 7 Acquired Thrombocytopenia
Thrombocytopenia Due to Platelet Alloimmunization Primary Thrombocytopenia
Ankrd26-Related Thrombocytopenia

Diseases related to Thrombocytopenia Due to Platelet Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1067)
# Related Disease Score Top Affiliating Genes
1 purpura 32.3 TNFSF13B THPO MPL ITGB3 ITGA2B GP1BA
2 thrombocytopenic purpura, autoimmune 31.3 THPO SOCS1 SELP MPL ITGB3 ITGA2B
3 acquired thrombocytopenia 31.2 THPO MPL ITGA2B GP1BA
4 evans' syndrome 31.1 THPO MPL CD4 CCR6
5 thrombocytosis 31.0 THPO SELP PF4 MPL
6 autoimmune disease 31.0 TNFSF13B ICOSLG FCGRT FCGR2B FCGR2A CCR6
7 deficiency anemia 30.9 THPO SELP MPL GP1BA CD19
8 colitis 30.8 SOCS1 ICOSLG CD4 CCR6
9 sarcoidosis 1 30.8 ICOSLG CD8A CD4 CCR6
10 exanthem 30.8 ICOSLG CD8A CD4 CCR6
11 bacterial infectious disease 30.7 ICOSLG FCGR2A CD4 CCR6
12 thrombosis 30.7 SELP PF4 ITGB3 ITGA2B GP1BA
13 immune deficiency disease 30.7 TNFSF13B ICOSLG FCGR2A CD8A CD4 CCR6
14 endocarditis 30.7 PF4 GP1BA FCGR2A
15 chickenpox 30.7 ICOSLG CD8A CD4 CD19 CCR6
16 heparin-induced thrombocytopenia 30.7 PF4 FCGR2A
17 thrombocytopenia 3 30.6 THPO MPL
18 splenic sequestration 30.6 THPO MPL ITGA2B CD4
19 igg4-related disease 30.6 TNFSF13B ICOSLG CCR6
20 myelodysplastic syndrome 30.6 THPO SOCS1 MPL ITGA2B CD8A
21 thyroid gland disease 30.6 ICOSLG CD4 CCR6
22 primary biliary cholangitis 30.6 SOCS1 ICOSLG CD4 CCR6
23 aplastic anemia 30.5 THPO MPL ITGB3 ITGA2B GP1BA CD4
24 infective endocarditis 30.5 PF4 ITGB3 GP1BA FCGR2A
25 poliomyelitis 30.5 FCGR2A CD8A CD4
26 mycobacterium tuberculosis 1 30.5 ICOSLG CD8A CD4 CCR6
27 thrombocytopenia 30.5 TNFSF13B THPO SELP PF4 MPL ITGB3
28 pfeiffer syndrome 30.5 CD8A CD4 CD19 CCR6
29 kawasaki disease 30.5 FCGR2B FCGR2A CD4
30 qualitative platelet defect 30.5 THPO PF4
31 childhood type dermatomyositis 30.4 ICOSLG CD4 CCR6
32 leukemia, acute lymphoblastic 30.4 THPO MPL ICOSLG CD8A CD4 CD19
33 thrombasthenia 30.4 SELP ITGB3 ITGA2B GP9 GP1BA
34 fetal and neonatal alloimmune thrombocytopenia 30.4 ITGB3 ITGA2B GP1BA
35 anemia, autoimmune hemolytic 30.4 TNFSF13B SOCS1 ICOSLG CD8A CD4 CD19
36 monoclonal gammopathy of uncertain significance 30.4 ICOSLG CD19 CCR6
37 myh-9 related disease 30.4 MPL GP9 GP1BA
38 coronary thrombosis 30.3 SELP ITGB3 ITGA2B GP1BA
39 polycythemia vera 30.3 THPO SELP PF4 MPL ITGB3
40 lymphadenitis 30.3 SOCS1 ICOSLG CD8A CD4 CCR6
41 common variable immunodeficiency 30.3 TNFSF13B ICOSLG FCGRT FCGR2B CD19
42 myeloma, multiple 30.3 TNFSF13B ICOSLG CD8A CD4 CD19 CCR6
43 pancytopenia 30.3 THPO MPL CD8A CD4 CD19
44 leukemia, chronic lymphocytic 30.3 TNFSF13B THPO ICOSLG CD8A CD4 CD19
45 arteriosclerosis 30.3 SELP ITGB3 ITGA2B GP1BA
46 connective tissue disease 30.3 TNFSF13B ICOSLG CD8A CD4 CCR6
47 cerebrovascular disease 30.3 SELP ITGB3 ITGA2B GP1BA
48 disease by infectious agent 30.2 ICOSLG FCGR2A CD8A CD4 CCR6
49 celiac disease 1 30.2 ICOSLG CD8A CD4 CD19 CCR6
50 arteritic anterior ischemic optic neuropathy 30.2 ITGB3 GP1BA

Graphical network of the top 20 diseases related to Thrombocytopenia Due to Platelet Alloimmunization:



Diseases related to Thrombocytopenia Due to Platelet Alloimmunization

Symptoms & Phenotypes for Thrombocytopenia Due to Platelet Alloimmunization

Human phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

31 (show all 9)
# Description HPO Frequency HPO Source Accession
1 thrombocytopenia 31 hallmark (90%) HP:0001873
2 thromboembolism 31 hallmark (90%) HP:0001907
3 petechiae 31 frequent (33%) HP:0000967
4 arterial thrombosis 31 frequent (33%) HP:0004420
5 gastrointestinal hemorrhage 31 occasional (7.5%) HP:0002239
6 epistaxis 31 occasional (7.5%) HP:0000421
7 gingival bleeding 31 occasional (7.5%) HP:0000225
8 bruising susceptibility 31 occasional (7.5%) HP:0000978
9 cerebral hemorrhage 31 very rare (1%) HP:0001342

MGI Mouse Phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.09 CCR6 CD19 CD4 CD8A FCGR2A FCGR2B
2 homeostasis/metabolism MP:0005376 9.83 CCR6 CD19 CD4 FCGR2A FCGR2B FCGRT
3 immune system MP:0005387 9.5 CCR6 CD19 CD4 CD8A FCGR2A FCGR2B

Drugs & Therapeutics for Thrombocytopenia Due to Platelet Alloimmunization

PubMed Health treatment related to Thrombocytopenia Due to Platelet Alloimmunization: 62

Treatment for immune thrombocytopenia (ITP) is based on how much and how often you're bleeding and your platelet count. Adults who have mild ITP may not need any treatment , other than watching their symptoms and platelet counts. Adults who have ITP with very low platelet counts or bleeding problems often are treated. The acute (short-term) type of ITP that occurs in children often goes away within a few weeks or months. Children who have bleeding symptoms, other than merely bruising (purpura ), usually are treated. Children who have mild ITP may not need treatment other than monitoring and followup to make sure their platelet counts return to normal.

Drugs for Thrombocytopenia Due to Platelet Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4 174722-31-7 10201696
2
Azathioprine Approved Phase 4 446-86-6 2265
3
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
4
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
5
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
6
alemtuzumab Approved, Investigational Phase 4 216503-57-0
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Hydroxychloroquine Approved Phase 4 118-42-3 3652
9
Clarithromycin Approved Phase 4 81103-11-9 84029
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Atorvastatin Approved Phase 4 134523-00-5 60823
12
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
13
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
14
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
15
Enoxolone Investigational Phase 4 471-53-4 18526330
16 Antineoplastic Agents, Immunological Phase 4
17 Antirheumatic Agents Phase 4
18 Proton Pump Inhibitors Phase 4
19 Antimitotic Agents Phase 4
20 Tubulin Modulators Phase 4
21 Anti-Ulcer Agents Phase 4
22 Antacids Phase 4
23 Antiparasitic Agents Phase 4
24 Antiprotozoal Agents Phase 4
25
Caffeic acid Phase 4 331-39-5, 501-16-6 689043
26 Antimalarials Phase 4
27 Autoantibodies Phase 4
28 Cytochrome P-450 Enzyme Inhibitors Phase 4
29 Cytochrome P-450 CYP3A Inhibitors Phase 4
30 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
31 Hypolipidemic Agents Phase 4
32 Lipid Regulating Agents Phase 4
33 Anticholesteremic Agents Phase 4
34 Tin Fluorides Phase 4
35 Vitamins Phase 4
36 Calciferol Phase 4
37 Nutrients Phase 4
38 Micronutrients Phase 4
39 Trace Elements Phase 4
40 Calcium, Dietary Phase 4
41 Vasoconstrictor Agents Phase 4
42
Calcium Nutraceutical Phase 4 7440-70-2 271
43
Pantoprazole Approved Phase 3 102625-70-7 4679
44
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7782-49-2
45
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
46
Dapsone Approved, Investigational Phase 3 80-08-0 2955
47
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
48
Chlorpheniramine Approved Phase 3 113-92-8, 132-22-9 2725
49
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
50
Oseltamivir Approved Phase 3 196618-13-0, 204255-11-8 65028

Interventional clinical trials:

(show top 50) (show all 279)
# Name Status NCT ID Phase Drugs
1 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
2 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
3 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
4 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
5 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Completed NCT03784898 Phase 4
6 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Completed NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
7 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Completed NCT02760251 Phase 4 romiplostim
8 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
9 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
10 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
11 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
12 A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP Patients Recruiting NCT04518475 Phase 4 eltrombopag combining rituximab;eltrombopag
13 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
14 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
15 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
16 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
17 A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
18 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in Immune Thrombocytopenia: a Prospective Multicenter Open Study Recruiting NCT03119974 Phase 4 Tpo-RA discontinuation
19 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT
20 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Not yet recruiting NCT04102033 Phase 4 Eltrombopag
21 Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim Not yet recruiting NCT04638829 Phase 4 Avatrombopag Oral Tablet
22 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Not yet recruiting NCT04094805 Phase 4 Rocaltrol;Dexamethasone
23 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
24 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
25 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
26 Efficacy of Helicobacter Pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients With Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study Unknown status NCT03177629 Phase 3 treatment : H. pylori eradication
27 A Phase III,Multicentre, Randomized, Double-Blind and Open-Label Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Idiopathic Thrombocytopenic Purpura Unknown status NCT03222843 Phase 3 Hetrombopag Olamine;matching placebo
28 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
29 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
30 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
31 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
32 A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) Unknown status NCT03164915 Phase 3
33 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
34 A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00415532 Phase 3 Medical Standard of Care for ITP
35 A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP Completed NCT01520909 Phase 3 Eltrombopag;Placebo
36 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT00508820 Phase 3
37 Randomized Study of the Treatment of Primary Immune Thrombocytopenic Purpura (ITP) in Newly Diagnosed Untreated Adult Patients. Comparison of Standard Dose Prednisone Versus High-dose Dexamethasone. Completed NCT00657410 Phase 3 dexamethasone;prednisone
38 Helicobacter Pylori Infection and Chronic Immune Thrombocytopenic Purpura in Children and Adolescents - A Randomized Controlled Trial Completed NCT01730352 Phase 2, Phase 3 H. pylori triple therapy
39 EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study. Completed NCT00351468 Phase 3 eltrombopag olamine (SB-497115-GR)
40 A Multicenter Open-labeled Pilot Study on Recombinant Human Thrombopoietin in Management of Immune Thrombocytopenia in Pregnancy Completed NCT02391272 Phase 3 rhTPO
41 Clinical Study to Evaluate the Efficacy and Safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in Adults Completed NCT00426270 Phase 3 Octagam 10%
42 Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura Completed NCT00699140 Phase 3
43 A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura Completed NCT00511147 Phase 3
44 Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study Completed NCT01621204 Phase 3 Eltrombopag;IVIG infusion
45 A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP) Completed NCT01444417 Phase 3 Romiplostim;Placebo
46 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study> Completed NCT00828750 Phase 3 Eltrombopag oral tablets
47 A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Rapidly Augmenting Platelet Counts in Childhood ITP. Completed NCT00376077 Phase 3 Methylprednisolone and IVIG;Placebo and IVIG
48 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura Completed NCT02076399 Phase 3 Fostamatinib disodium;Placebo
49 An Open-label, Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT00168038 Phase 3
50 A Rand. Trial Comp Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine, and Prednisone) in Patients With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment Completed NCT00774202 Phase 2, Phase 3 Rituxan, Cyclophosphamide, Vincristine, Prednisone;Higher Dose of Rituximab

Search NIH Clinical Center for Thrombocytopenia Due to Platelet Alloimmunization

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Azathioprine
Cyclophosphamide
Immunoglobulins, Intravenous
Intramuscular immunoglobulin
Rho(D) Immune Globulin, human
Venoglobulin-I
Vinblastine
Vinblastine Sulfate

Genetic Tests for Thrombocytopenia Due to Platelet Alloimmunization

Genetic tests related to Thrombocytopenia Due to Platelet Alloimmunization:

# Genetic test Affiliating Genes
1 Autoimmune Thrombocytopenia 29

Anatomical Context for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards organs/tissues related to Thrombocytopenia Due to Platelet Alloimmunization:

40
Bone Marrow, T Cells, Spleen, Myeloid, B Cells, Bone, Endothelial

Publications for Thrombocytopenia Due to Platelet Alloimmunization

Articles related to Thrombocytopenia Due to Platelet Alloimmunization:

(show top 50) (show all 3702)
# Title Authors PMID Year
1
Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia. 61
33357172 2021
2
Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project. 61
33462778 2021
3
Fatigue perception in a cohort of children with chronic immune thrombocytopenia and their caregivers using the PedsQL MFS: Real-life multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). 61
33274837 2021
4
Myeloid-derived suppressor cells anticipate sustained treatment response in newly-diagnosed and persistent primary immune thrombocytopenia. 61
33338696 2021
5
Romiplostim as Adjunctive Treatment of Refractory Amegakaryocytic Immune Thrombocytopenia in a Dog. 61
33115689 2021
6
Extracellular vesicles derived from miR-199a-5p-modified adipose-derived mesenchymal stem cells alleviate immune thrombocytopenia by inhibiting T helper 17 differentiation. 61
33402685 2021
7
Adult-diagnosed Chronic Granulomatous Disease: The Need to Increase Awareness. 61
33605407 2021
8
Abnormal expression of autophagy-related proteins in immune thrombocytopenia. 61
33140452 2021
9
Primary immunodeficiencies, autoimmune hyperthyroidism, coeliac disease and systemic lupus erythematosus in childhood immune thrombocytopenia. 61
33025591 2021
10
Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. 61
33586606 2021
11
Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life. 61
33107998 2021
12
High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. 61
33125750 2021
13
I-WISh: A wish list for immune thrombocytopenia quality of life indicators becomes reality. 61
33219702 2021
14
Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: development and validation of the MONITOR model in a nationwide multicenter study. 61
33606900 2021
15
Immune thrombocytopenia induced by beta-lactam antibiotics: Cross-reactions of responsible antibodies with other beta-lactam drugs. 61
33580978 2021
16
Effect of plasma exosomes on endothelial cell tight junction proteins in SLE patients with immune thrombocytopenia. 61
33599860 2021
17
Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. 61
33170956 2021
18
Splenectomy in zebrafish: a new model for immune thrombocytopenia. 61
33539196 2021
19
iTRAQ-based quantitative proteomics analysis of immune thrombocytopenia patients before and after Qishunbaolier treatment. 61
33140498 2021
20
Histology of the spleen in immune thrombocytopenia: clinical-pathological characterization and prognostic implications. 61
33190299 2021
21
Variables related to chronic immune thrombocytopenia: experience from a single center and comparison to a meta-analysis. 61
33594540 2021
22
The role and mechanism of miR-557 in inhibiting the differentiation and maturation of megakaryocytes in immune thrombocytopenia. 61
33586614 2021
23
Clinical association between thyroid disease and immune thrombocytopenia. 61
33165625 2021
24
An evaluation of avatrombopag for the treatment of thrombocytopenia. 61
33095074 2021
25
Temporal trends and outcome of splenectomy in adults with immune thrombocytopenia in the USA. 61
33560468 2021
26
The association of lymphocyte phenotypes and outcomes after discontinuing eltrombopag in immune thrombocytopenia. 61
33529437 2021
27
Incidence and prevalence of immune thrombocytopenia under the copayment waiver policy for pediatric patients in Korea: Data from the National Health Claims Database. 61
33593162 2021
28
How I treat immune thrombocytopenia - a global view. 61
33570179 2021
29
Eltrombopag inhibits Type I interferon-mediated antiviral signaling by decreasing cellular iron. 61
33539815 2021
30
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients. 61
32979651 2021
31
Impact of autoimmune cytopenias on severity of childhood-onset systemic lupus erythematosus: A single-center retrospective cohort study. 61
33108953 2021
32
Response to: 'Correspondence on 'Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study'' by Maquet et al. 61
33441296 2021
33
[Secondary ITP in adults]. 61
33139079 2021
34
How I manage cyclic thrombocytopenia. 61
33197928 2021
35
Update on the Use of Intravenous Immunoglobulin in Pregnancy. 61
33386311 2021
36
Cardiac sarcoidosis requiring ICD placement and immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis. 61
33160137 2021
37
Chronic Immune Thrombocytopenia and Hashimoto's Hypothyroidism in an Adolescent: Presentation and Implications. 61
33604093 2021
38
Secondary immune thrombocytopenia in children: characteristics and outcome of a large cohort from two Spanish Centers. 61
33460494 2021
39
IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans. 61
33512707 2021
40
[Immune thrombocytopenia: From pathogenesis to treatment]. 61
32741715 2021
41
Jianpi Yiqi Shexue ameliorates immune thrombocytopenia related fatigue by regulating mitochondrial function. 61
33440960 2021
42
Vitamin D Insufficiency is Not Associated With Pediatric and Adolescent Immune Thrombocytopenia: A Study in Conjunction With its Receptor Genetic Polymorphisms. 61
32287103 2021
43
Acquired amegakaryocytic thrombocytopenia after durvalumab administration. 61
33431742 2021
44
The Clinical Conundrum of Managing Ischemic Stroke in Patients with Immune Thrombocytopenia. 61
32646527 2021
45
Immune thrombocytopenia associated with tuberculosis - A case report. 61
33304813 2021
46
[Challenges and potential solutions in first-line treatments for immune thrombocytopenia in adults]. 61
32713675 2021
47
[Immune thrombocytopenia: state of the art and perspectives]. 61
33261888 2021
48
Risk factors and predictors of treatment responses and complications in immune thrombocytopenia. 61
33515047 2021
49
Evolving treatment modalities for immune thrombocytopenia in adults. 61
33552432 2021
50
Comparative Utilization and Efficacy of Thrombopoietin Receptor Agonists in Relapsed/Refractory Immune Thrombocytopenia. 61
33491968 2021

Variations for Thrombocytopenia Due to Platelet Alloimmunization

ClinVar genetic disease variations for Thrombocytopenia Due to Platelet Alloimmunization:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SOCS1 NM_003745.1(SOCS1):c.368C>G (p.Pro123Arg) SNV Likely pathogenic 977212 16:11348968-11348968 16:11255111-11255111
2 SOCS1 NM_003745.1(SOCS1):c.24del (p.Ala9fs) Deletion Likely pathogenic 977213 16:11349312-11349312 16:11255455-11255455
3 SOCS1 NM_003745.1(SOCS1):c.476_480dup (p.Met161fs) Microsatellite Likely pathogenic 977214 16:11348855-11348856 16:11254998-11254999

Expression for Thrombocytopenia Due to Platelet Alloimmunization

Search GEO for disease gene expression data for Thrombocytopenia Due to Platelet Alloimmunization.

Pathways for Thrombocytopenia Due to Platelet Alloimmunization

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to KEGG:

36
# Name Kegg Source Accession
1 Phagosome hsa04145
2 Osteoclast differentiation hsa04380
3 Fc gamma R-mediated phagocytosis hsa04666

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 TNFSF13B SOCS1 ITGB3 ITGA2B ICOSLG FCGR2B
2
Show member pathways
13.3 TNFSF13B THPO PF4 ITGB3 ITGA2B CD4
3
Show member pathways
13.16 THPO SELP PF4 MPL ITGB3 ITGA2B
4 12.44 TNFSF13B SOCS1 MPL CD8A CD19
5
Show member pathways
12.05 PF4 GP9 GP5 GP1BA
6
Show member pathways
12.05 ITGB3 ITGA2B GP9 GP5 GP1BA
7 12.01 SELP ICOSLG CD8A CD4
8 11.9 SOCS1 ITGB3 FCGR2B FCGR2A
9 11.83 ITGB3 ITGA2B GP9 GP5 GP1BA FCGR2A
10 11.78 SELP FCGR2B FCGR2A
11 11.71 ITGB3 ITGA2B FCGR2A
12
Show member pathways
11.69 THPO MPL ITGB3 ITGA2B GP9 GP5
13 11.67 CD8A CD4 CCR6
14 11.63 CD8A CD4 CD19
15 11.6 THPO ITGB3 ITGA2B GP9 GP5 GP1BA
16 11.55 SOCS1 SELP ITGB3
17 11.54 TNFSF13B ICOSLG FCGR2B FCGR2A CCR6
18 11.44 ITGB3 ITGA2B FCGR2A
19 11.42 ITGB3 ITGA2B GP9
20 11.41 ITGB3 ITGA2B GP9 GP5
21 11.39 THPO MPL ITGB3 ITGA2B GP5 GP1BA
22 11.27 CD8A CD4 CD19
23 10.92 TNFSF13B THPO PF4 ITGB3 ITGA2B
24 10.77 GP9 GP5 GP1BA
25 10.54 GP9 GP5 GP1BA

GO Terms for Thrombocytopenia Due to Platelet Alloimmunization

Cellular components related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.31 TNFSF13B SELP MPL ITGB3 ITGA2B ICOSLG
2 integral component of membrane GO:0016021 10.16 TNFSF13B SELP MPL ITGB3 ITGA2B ICOSLG
3 plasma membrane GO:0005886 10.06 TNFSF13B SELP MPL ITGB3 ITGA2B ICOSLG
4 cell surface GO:0009986 9.85 MPL ITGB3 ITGA2B GP1BA CD4 CCR6
5 integral component of plasma membrane GO:0005887 9.7 SELP ITGB3 GP9 GP5 GP1BA FCGR2B
6 platelet alpha granule membrane GO:0031092 9.5 SELP ITGB3 ITGA2B
7 external side of plasma membrane GO:0009897 9.28 SELP ITGA2B ICOSLG FCGRT FCGR2B CD8A

Biological processes related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.01 TNFSF13B ICOSLG FCGR2A CD8A CD4 CD19
2 cell adhesion GO:0007155 9.87 SELP ITGB3 ITGA2B GP9 GP5 GP1BA
3 cell surface receptor signaling pathway GO:0007166 9.83 GP1BA FCGR2B FCGR2A CD8A CD4
4 blood coagulation GO:0007596 9.81 ITGB3 GP9 GP5 GP1BA
5 regulation of immune response GO:0050776 9.77 TNFSF13B FCGR2B FCGR2A CD8A CD19
6 platelet degranulation GO:0002576 9.71 SELP PF4 ITGB3 ITGA2B
7 regulation of megakaryocyte differentiation GO:0045652 9.7 PF4 ITGA2B GP1BA
8 immune response GO:0006955 9.7 TNFSF13B PF4 FCGRT FCGR2B CD8A CD4
9 hemostasis GO:0007599 9.67 GP9 GP5 GP1BA
10 T cell activation GO:0042110 9.63 ICOSLG CD8A CD4
11 immunoglobulin mediated immune response GO:0016064 9.56 FCGR2B CD19
12 positive regulation of leukocyte migration GO:0002687 9.55 SELP ITGA2B
13 thrombopoietin-mediated signaling pathway GO:0038163 9.48 THPO MPL
14 blood coagulation, intrinsic pathway GO:0007597 9.43 GP9 GP5 GP1BA
15 platelet aggregation GO:0070527 9.26 MPL ITGB3 ITGA2B GP1BA
16 platelet activation GO:0030168 9.02 PF4 ITGB3 GP9 GP5 GP1BA

Molecular functions related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibrinogen binding GO:0070051 9.16 ITGB3 ITGA2B
2 coreceptor activity GO:0015026 9.13 ITGB3 CD8A CD4
3 IgG binding GO:0019864 8.8 FCGRT FCGR2B FCGR2A

Sources for Thrombocytopenia Due to Platelet Alloimmunization

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....